Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MRG007 · 1 trial · 4 indications
Adverse events that are fatal, life-threatening, or result in hospitalization or prolonged hospitalization, persistent or significant disability/incapacity/substantial disruption of the ability to lead a normal life, congenital anomaly/birth defect or major medical events or reactions
AEs that occur or worsen on or after the first dose of study treatment
Any reaction, side effect, or untoward event that occurs during the course of the clinical trial is considered related to the study drug.
ORR is defined as the proportions of patients with a complete response (CR) and partial response (PR). ORR will be assessed according to RECIST v1.1.
| Arm | Type | Description |
|---|---|---|
| MRG007 | EXPERIMENTAL | - |
| MRG007 and Bevacizumab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MRG007 | DRUG | MRG007 will be administrated as specified in the protocol. |
| MRG007 and Bevacizumab | DRUG | MRG007 will be administered as specified in the protocol |
1. Willing to sign the informed consent form and follow the requirements specified in the protocol. 2. Life expectancy ≥ 3 months. 3. Tumor specimen available for CDH17 testing, or agree to biopsy at baseline. 4. Patients with histologically and cytologically confirmed advanced or metastatic solid t...
MRG007 is an investigational small molecule being developed for the treatment of locally advanced or metastatic solid tumors, including colorectal cancer, gastric cancer, and pancreatic cancer. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
MRG007 is being developed by ArriVent BioPharma, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol AVBP. The company is conducting clinical trials for this investigational oncology drug candidate.
MRG007 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The ongoing Phase 1 study is actively recruiting participants to evaluate the drug in patients with advanced solid tumors.
MRG007 is being studied in a single active Phase 1 clinical trial with the identifier NCT07066657. This trial is titled 'A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors' and is recruiting participants in the United States and China.
Yes, MRG007 is also known as ARR-217. The clinical trial NCT07066657 refers to the drug as MRG007 (ARR-217), indicating that both names refer to the same investigational compound being developed by ArriVent BioPharma.
The Phase 1 clinical trial of MRG007 (NCT07066657) has a planned enrollment of 572 participants. The study is currently recruiting patients aged 18 years and older with locally advanced or metastatic solid tumors, including colorectal, gastric, and pancreatic cancers.